European Monitoring Centre for Drugs and Drug Addiction
12
World Health Organisation (WHO)
11
IACAPAP
9
et al.
8
Organización Mundial de la Salud OMS
6
Ministry of Health, Rwanda
5
Organisation Mondiale de la Santé OMS
5
WHO
5
Drugs for Neglected Diseases initiative DNDi
4
Indian Council of Medical Research (ICMR)
4
Ministry of Health and Social Services (MOHSS)
4
Ministry of Health, Kenya
4
OPAS
4
Organisation mondiale de la Santé
4
Organisation Mondiale de la Santé OMS
4
Pan American Health Organisation PAHO
4
Pan American Health Organization
4
Africa CDC
3
C. Carandang
3
C. Gray
3
H. Marval-Ospino
3
United Nations Office on Drugs and Crime
3
Wiedenmayer, K. et al.
3
Africa CDC Centres for Disease Control and Prevention
2
Africa Center for Disease Control and Prevention
2
African Union
2
C. Bachmann
2
Centers for Disease Control and Prevention CDC
2
European Union
2
Ministerio de Salud Argentina
2
Ministerio de Salud Chile
2
Ministerio de Salud Pública y Bienestar Social Paraguay
2
Ministry of Health and Sanitation Sierra Leone
2
Ministry of Health, Gabarone, Botswana
2
National Centre for Disease Control (NCDC)
2
National Vector Borne Disease Control Programme (NVBDCP)
2
Organisation de la Santé Mondiale
2
Organización Mundial de Saude and OPAS
2
Pharmacy Board Sierra Leone
2
Republic of Kenya, Ministry of Health
2
Robert-Koch-Institut RKI
2
S. MacPhee
2
T. Lempp
2
United Nations
2
United Nations Office on Drug and Crime UNODC
2
Zambia Medicines Regulatory Authority (ZAMRA)
2
2012
1
2016
1
A. K. Lam
1
A. Martin
1
A. Smajljaj
1
A. Sondheimer
1
A. Sönnerborg
1
A. Xhuvani
1
A.Ramesh
1
Abdulrahim, D.
1
ACCSI, et al.
1
Adrian Sondheimer
1
Agence Japonaise de Cooperation International Kokusai Kogyo Co., Ltd.
1
Agency for Toxic Substances & Disease Registry
1
AIEPI Hospitalario
1
American Chemistry Council
1
and O. Bowden-Jones
1
ANDEMIA
1
Australian National Clinical Evidence Taskforce
1
Berkley, James A.
1
BioNTech
1
Bolivia, Ministerio de Salud, Gobierno de Estado Plurinacional s
1
Bundeszentrale für gesundheitliche Aufklärung
1
Butkus, R. A.
1
Butterworth Heinemann
1
C. Giannou, M. Baldan and A. Molde
1
C. Kalpaki, M. Moudatsou, E. Maraki, et al.
1
Centers for Disease Control and Prevention (CDC)
1
Centre Anti Poison du Maroc
1
Centre d’excellence Africain pour la santé de la Mère et de l’enfant (CEA-SAMEF)
1
Centre for Antibiotic Resistance Research (CARe), University of Gothenburg
1
Chatanga, Peter
1
Chișinău
1
CODEVIDA, Coalición de Organizaciones por el Derecho a la Salud y a la Vida
1
Congressional Research Service
1
Cordner, S.
1
Cureus
1
D. de Lange, D. Radeloff
1
D. Raben
1
D. Radeloff
1
D.de Lange
1
Dadvand, P.
1
Damialis, A.
1
DATER House
1
David P.M., Le Dévédec N. et al.
1
Dermatol Venez, Univerisdad Central de Venezuela
1
Deutsche Hauptstelle für Suchtfragen e.V.
1
Dilys Morgan, Hilary Kirkbride and Bengü Said
1
Directorate General of Health Services Ministry of Health & Family Welfare Government of the People’s Republic of Bangladesh
1
Dr. X. Zeka
1
Drug Safety Monitoring Programme
1
Drugs Advisory Board, Republic of Botswana (Gabarone, Botswana)
1
DTG
1
E. Gjergji
1
E. Subata
1
Elsevier Ltd.
1
EMCDDA
1
et al
1
Europäische Beobachtungsstelle für Drogen und Drogensucht (EMCDDA)
1
European Centre for Disases Prevention and Control ECDC
1
European Scientific Journal
1
F. Fezeu
1
Fairlamb, A.H.
1
Federal Ministries of Agriculture, Environment and Health
1
Food and Agriculture Organization (FAO)
1
Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO)
1
Food and Agriculture Organization of the United Nations FAO
1
Food and Drug Authority (FDA), Ghana
1
Food and Drugs Authority (FDA), Ghana
1
Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA)
1
Frewer, A.
1
Friedman, J.F. et al.
1
Fuller, R.
1
Gascon M., Markevych I.
1
GBD 2019 Blindness and Vision Impairment Collaborators
1
GBD 2019 Tuberculosis Collaborators
1
GBD2019 Dementia Forecasting Coolaborators
1
Global smart
1
Gobierno Bolivariano de Venezuela, UNICEF, et al.
1
Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals
1
Government of Kenya
1
Government of South Africa
1
Government of Tanzania
1
Gutiéerrez, J.
1
Gutiérrez, J.
1
H. Furtmayr, K. Krása
1
Haywood, A. and B. D Glass
1
Health Care without Harm
1
Horn, D.
1
Human Rights Watch
1
ICF International
1
ICRC
1
IFRC
1
Indian Council for Medical Research (ICMR)
1
Indian Council of Medical Research (ICMR) & Department of Biotechnology
1
Instituti Shendetit Public
1
International Bureau for Epilepsy
1
International Committee of the Red Cross ICRC
1
International Dairy Federation
1
International Federation of Medical Students’ Associations (IFMSA)
1
International League against Epilepsy
1
International Pharmaceutical Federation FIP
1
Iosue, S.
1
J Pharm Pharm Sci
1
J. M. Rey. M. Irarrázaval
1
J. O. Errecalde
1
J. Sekulić
1
J.-J. Kim
1
Jackson, J., Kheng Heng, L., Eklund, G. et al.
1
Joseph M Rey
1
Kadam. A.
1
Katrin Leitmeyer
1
Kingdom of Swaziland Ministry of Health
1
Koren, H.
1
L'avoisier
1
L. Savikj
1
Laboratorio Central de Salud Publica
1
Liberia Medicines and Health Products Regulatory Authority (LMHRA)
1
Lisa Myers, Laura Theytaz-Bergman
1
M. Hodaj
1
M. Vitoriaa
1
Mapako, Tonderai, Simbarashe Rusakaniko, Maarten J. Postma, Marinus van Hulst, Janet Dzangare, Stellah Ngwende, John Mandisarisa, Ponesai Nyika, David A. Mvere, Owen Mugurungi, and Mufuta Tshimanga
1
Marie-Noel Bruné Drisse and Fiona Goldizen
1
Mario R Dal Poz, Neeru Gupta, Estelle Quain and Agnes LB Soucat
Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT).
Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s.
Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher...e the genetic mechanism has been established.
The current goal of elimination of HAT as a public health problem by 2020 may be undermined by the emergence and spread of resistance to current or new drugs.
Insights into potential resistance mechanisms for current and new drugs will facilitate predictions of the likelihood of resistance and will also facilitate rational approaches to minimizing, monitoring, and tackling the future emergence of resistance.more
Leishmaniasis is a climate-sensitive disease. Changes in
temperature, rainfall, and humidity can have strong impacts on
the sandfly vector, altering their distribution and influencing their
survival and population sizes. Increased temperatures shorten
vector development time, reduce Leishmania p...arasite incubation
time, and increase vector biting rates, allowing transmission
in areas not previously endemic for the disease. Poor and
marginalized communities will be hit disproportionately harder by
the effects of climate change, and droughts, famines, and floods
can also lead to displacement and migration of immunologically
naive people to areas where leishmaniasis is endemic, posing a
threat of leishmaniasis outbreaks.more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.more
The goal of the global outbreak response for monkeypox is to stop human-to-human transmission of monkeypox, with a priority focus on communities at high risk of exposure which may differ according to context, and to effectively use strong public health measures to prevent onward spread of the diseas...e. Judicious use of vaccines can support this response. This interim guidance, developed with the advice and support of the Strategic Advisory Group of Experts (SAGE) Working Group on smallpox and monkeypox vaccines, provides the first WHO recommendations on vaccines and immunization for monkeypox. Key points follow.more
The project was developed by the International Federation of Medical Students’ Associations (IFMSA), in line with the Federation’s statement “a world in which students are equipped with knowledge, skills and value to take on health leadership roles locally and globally so to... shape a sustainable future”. This was supported by an ongoing and vital engagement from the World Health Organization (WHO) and their work the United Nations Alliance on Climate Change Education, Training and Public Awareness. The overall objective was to create a “all in one” type of resource to bring together climate change, health and youth advocacy.more
Wiedenmayer, K. et al.World Health Organization (WHO), International Pharmaceutical Federation (FIP)
(2006)
C_WHO
English version - This handbook sets out a the new paradigm for pharmacy practice. Its aim is to guide pharmacy educators in pharmacy practice, to educate pharmacy students and to guide pharmacists in practice to update their skills. The handbook, which brings together practical tools and knowledge,... has been written in response to a need to define, develop and generate global understanding of pharmaceutical care at all levels.more
Proper and dignified management of the dead in disasters is one of the three key pillars of humanitarian response and a fundamental factor in facilitating identification of the deceased and helping families discover the fate of their loved ones. This second and updated edition of this hugely success...ful manual provides practical and easy-to-follow guidelines on the recovery, documentation and storage of the remains of individuals who have died in disasters, helping first responders ensure that the dead are treated with respect and that information crucial for their subsequent identification is recorded. This revised edition incorporates experience gained in recent catastrophes, such as the 2013 Typhoon Haiyan in the Philippines, the 2014/15 Ebola epidemic in West Africa and the 2015 earthquake in Nepal.more
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document provides interim guidance to countries on testing considerations and strategies for suspect cases of severe acute hepatitis of unknown aetiology in children. It is primarily intended for clinical, programmatic, laboratory and diagnostic stakeholders across Member States and national pu...blic health authorities involved in the identification and investigation of cases of severe acute hepatitis in children.
This document is part of a package of guidance for this event, which includes suggested minimum reporting variables and a clinical Case Report Form support Member States with case investigation and reporting.more
Updated 2 June 2022.#
This entry contains the Status Report of WHO Collaborating Centres in the Americas by Country and a new document with information of Collaborating Centres by Outcome of the Strategic Plan of the Pan American Health Organization 2020‑2025.
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...ed: version 15 March 2022.more
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...is document has been updated: version 15 March 2022.more
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...ed below.
This document has been updated: Version 15 March 2022.more
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.more